You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Analysts. Can’t live with ’em, can’t profit without them — or at least that’s one view that some industry watchers in genomics have been airing recently. Analyst coverage, they argue, contributes to a vicious cycle that looks like this:
GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.